Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate

MLA

Johann Stanek, et al. “Synthesis and in Vivo Evaluation of the Putative Breast Cancer Resistance Protein Inhibitor [11C]Methyl 4-((4-(2-(6,7-Dimethoxy-1,2,3,4-Tetrahydroisoquinolin-2-Yl)Ethyl)Phenyl)Amino-Carbonyl)-2-(Quinoline-2-Carbonylamino)Benzoate.” Nuclear Medicine and Biology, vol. 37, July 2010, pp. 637–44. EBSCOhost, https://doi.org/10.1016/j.nucmedbio.2010.02.008.

APA

Johann Stanek, Thomas Wanek, Thomas Erker, Claudia Kuntner, Bernd Dörner, Severin Mairinger, Jens P. Bankstahl, Christoph Baumgartner, Markus Müller, Oliver Langer, Florian Bauer, Wolfgang Löscher, & Marion Bankstahl. (2010). Synthesis and in vivo evaluation of the putative breast cancer resistance protein inhibitor [11C]methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)amino-carbonyl)-2-(quinoline-2-carbonylamino)benzoate. Nuclear Medicine and Biology, 37, 637–644. https://doi.org/10.1016/j.nucmedbio.2010.02.008

Chicago

Johann Stanek, Thomas Wanek, Thomas Erker, Claudia Kuntner, Bernd Dörner, Severin Mairinger, Jens P. Bankstahl, et al. 2010. “Synthesis and in Vivo Evaluation of the Putative Breast Cancer Resistance Protein Inhibitor [11C]Methyl 4-((4-(2-(6,7-Dimethoxy-1,2,3,4-Tetrahydroisoquinolin-2-Yl)Ethyl)Phenyl)Amino-Carbonyl)-2-(Quinoline-2-Carbonylamino)Benzoate.” Nuclear Medicine and Biology 37 (July): 637–44. doi:10.1016/j.nucmedbio.2010.02.008.